Medicenna Therapeutics Corp.
MDNA.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 853.60K | 1.20M | 1.32M | 919.30K | 1.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.98M | 3.66M | 4.05M | 2.95M | 2.97M |
| Operating Income | -3.98M | -3.66M | -4.05M | -2.95M | -2.97M |
| Income Before Tax | 827.10K | -3.71M | -3.05M | -2.66M | -10.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 827.10K | -3.71M | -3.05M | -2.66M | -10.31M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 827.10K | -3.71M | -3.05M | -2.66M | -10.31M |
| EBIT | -3.98M | -3.66M | -4.05M | -2.95M | -2.97M |
| EBITDA | -3.98M | -3.66M | -4.05M | -2.95M | -2.97M |
| EPS Basic | 0.01 | -0.05 | -0.04 | -0.04 | -0.15 |
| Normalized Basic EPS | 0.01 | -0.03 | -0.02 | -0.02 | -0.09 |
| EPS Diluted | 0.01 | -0.05 | -0.04 | -0.04 | -0.15 |
| Normalized Diluted EPS | 0.01 | -0.03 | -0.02 | -0.02 | -0.09 |
| Average Basic Shares Outstanding | 78.19M | 78.01M | 76.84M | 73.62M | 69.64M |
| Average Diluted Shares Outstanding | 78.19M | 78.01M | 76.84M | 73.62M | 69.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |